Solid IO

Solid IO is a Helsinki-based deep tech startup pioneering a tumor-on-chip platform designed to transform precision oncology and immunotherapy. By creating patient-specific models that replicate the tumor microenvironment, the platform aims to predict treatment responses in real-time, enabling more informed clinical decisions and reducing trial-and-error for patients. The company is currently in the research and development phase, collaborating with pharmaceutical and clinical partners to validate its technology and advance towards clinical application. Solid IO represents a convergence of bioengineering, AI, and translational cancer biology with the goal of making personalized cancer medicine a standard of care.

Patient-specific organ-on-chip (tumor-on-chip) platform that replicates the tumor microenvironment, including immune cell interactions, for real-time testing of immunotherapy responses. Combines bioengineering, microfluidics, and AI-driven analytics.

Solid IO competes in the organ-on-chip and functional precision oncology space. Direct competitors include other OoC companies like Emulate, Mimetas, and CN Bio. It also faces competition from patient-derived organoid platforms and AI/ML-based diagnostic tools that use genomic or histopathological data. Its differentiation hinges on the specific focus on the immuno-oncology microenvironment and real-time, dynamic analysis.